Currently, there are 1.12M common shares owned by the public and among those 0.44M shares have been available to trade.
The company’s stock has a 5-day price change of 133.59% and -8.78% over the past three months. PRTG shares are trading -75.16% year to date (YTD), with the 12-month market performance down to -64.41% lower. It has a 12-month low price of $2.10 and touched a high of $40.80 over the same period. PRTG has an average intraday trading volume of 911.60K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 107.62%, 76.58%, and 59.45% respectively.
Institutional ownership of Portage Biotech Inc (NASDAQ: PRTG) shares accounts for 19.61% of the company’s 1.12M shares outstanding.
It has a market capitalization of $10.12M and a beta (3y monthly) value of 1.54. The earnings-per-share (ttm) stands at -$65.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 32.52% over the week and 16.22% over the month.
Looking at the support for the PRTG, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on July 18, 2022, with the firm’s price target at $26. H.C. Wainwright coverage for the Portage Biotech Inc (PRTG) stock in a research note released on March 07, 2022 offered a Buy rating with a price target of $32. Oppenheimer was of a view on September 21, 2021 that the stock is Outperform, while B. Riley Securities gave the stock Buy rating on September 02, 2021, issuing a price target of $40. Cantor Fitzgerald on their part issued Overweight rating on August 19, 2021.
